<DOC>
	<DOCNO>NCT01552018</DOCNO>
	<brief_summary>Dipeptidyl peptidase 4 ( DPP-4 ) inhibitor approve add therapy improve glycaemic control Type 2 Diabetes Mellitus ( T2DM ) . DPP-4 inactivates incretin hormone glucagon-like peptide 1 ( GLP-1 ) . Inhibiting inactivation GLP-1 lead increase insulin- reduce glucagon secretion meal . DPP-4 show present atherosclerotic plaque . DPP-4 protease substrates include cytokine chemokines associate atherosclerosis/inflammation . The purpose study explore effect 3 month intervention DPP-4 inhibitor saxagliptin biomarkers related atherosclerosis patient stable coronary artery disease ( CAD ) T2DM , circulate level expression level circulate monocyte adipose tissue . A reduction marker associate atherosclerosis could indicate antiatherosclerotic effect DPP-4 inhibitor beyond glycaemic control alone . Due reduce sample size ( recruitment problem ) main focus change cellular aspect gene regulation ( initially secondary outcome measure ) .</brief_summary>
	<brief_title>Saxagliptin Atherosclerosis</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Patients &gt; 18 , &lt; 80 year old , type 2 diabetes mellitus angiographically proven coronary artery disease . HbA1c &gt; 6.5 % treatment either metformin and/or glimepiride . Allergy hypersensitivity drug 's component . Heart failure NYHA class III IV . Severe liver failure , moderate severe kidney failure Malignant disease . Active infectious disease . Acute coronary syndrome last 3 month . Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>